Agile Therapeutics was founded in 1997 on the principle that women want and need more convenient contraceptive options. Agile has a pipeline of investigational contraceptive products in late-stage clinical development that represent significant near-term revenue potential. These contraceptives are transdermal patches based on a proprietary delivery technology developed by Agile. The company will compete in the more than $4 billion contraceptive market.
The patches use the proprietary transdermal delivery technology developed by Agile, Skinfusion®, and are designed to be soft and flexible with a silky feel. The Agile patch has demonstrated favorable wearability and adhesion in clinical trials.
Agile Therapeutics is headquartered in Princeton, NJ.
Agile Therapeutics Commercial Head presents at 7th Annual Digital Pharma East – Working with Patient Advocacy Groups to develop an Integrated Unbranded Education and Adherence Program: Experience in Contraception in Young Women.